Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. 

Miocardiopatía hipertrófica: análisis de una serie histórica

There is also alcohol septal ablation as an alternative strategy, which different studies have found favorable, even though its true benefit remains unclear, as well as the group of patients that would benefit from this treatment.  

The study looked at patients undergoing surgical septal myectomy and alcohol septal ablation (ASA) since 1998 to 2019 at the Mayo Clinic and the Fuwai Hospital. In all, it included 3274 patients undergoing septal myectomy and 585 ASA.

Primary end point was all cause mortality.

The ASA patients were older, had more hypertension, diabetes, kidney failure and heart disease, but had smaller septal thickness (19 mm vs 20 mm p=0.007) and no difference in gradient. 

At 30 days, mortality resulted similar: 0.7% vs 0.3% for ASA and septal myectomy respectively.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy.

At 10 years, primary end point was higher in patients who had received ASA (26.1% vs. 8.2%), which was maintained after adjusting for variables such as age, sex and comorbidities (HR: 1.68; 95% CI: 1.29-2.19; P < 0.001).

Other parameters associated to mortality were functional class III-IV, obstructive pulmonary disease, stroke, atrial fibrillation, renal failures, diabetes and septal thickness, 

Conclusion

In patients with hypertrophic cardiomyopathy, alcohol septal ablation is associated with higher mortality in the long term, regardless other known factors, even though it might be affected by confounding factors overlooked as patient characteristics. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org .

Original Title: Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive. Hypertrophic Cardiomyopathy.

Reference: Hao Cui, et al. (J Am Coll Cardiol 2022;79:1647–1655).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...